Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.305 USD | +2.93% | -10.65% | -34.39% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
05-10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.